Phuturdex › Diseases › Nasopharyngeal neoplasm
Drugs in development · updated 30 October 2026
Nasopharyngeal neoplasm: drugs in development
As of 30 October 2026 there are 26 active clinical trials (recruiting or ongoing, phases I–III) on 32 drugs for nasopharyngeal neoplasm. 18 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AnlotinibAL3818, Anrotinib | III | 2 | NCT07385079 |
| BenmelstobartTQB2450 | III | 1 | NCT07385079 |
| CadonilimabAK104, Candonilimab | III | 1 | NCT05587374 |
| CamrelizumabCarrelizumab, Carilizumab | III | 1 | NCT04453826 |
| Chemoradiotherapy | III | 1 | NCT04453826 |
| QL1706 | III | 1 | NCT06749899 |
| AdebrelimabSHR-1316, Adebelimab | II | 1 | NCT06349889 |
| AVZO-1418 | I–II | 1 | NCT07038343 |
| Becotatug VedotinMRG003 | II | 1 | NCT07524413 |
| JMT101 | II | 1 | NCT06892431 |
| Nituzumab | II | 1 | NCT06414577 |
| PucotenlimabHX008 | II | 1 | NCT07524413 |
| STAR0602 | I–II | 1 | NCT05592626 |
| VK-2019 | II | 1 | NCT04925544 |
| FianlimabREGN3767 | I | 1 | NCT07650266 |
| Izalontamab brengitecanBL-B01D1, BMS-986507 | I | 1 | NCT05983432 |
| KFA115 | I | 1 | NCT05544929 |
| RimiducidAP1903 | I | 1 | NCT05239143 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CisplatinCis Platinum, Cisplatine | III | 9 | NCT07385079 |
| GemcitabineGemcitabin, Gemzar | III | 9 | NCT07385079 |
| Fluorouracil5-Fluorouracil, Adrucil | III | 2 | NCT03840421 |
| TislelizumabTisleizumab, Tiselizumab | III | 1 | NCT07373990 |
| Bevacizumabavastin, MVASI | I–II | 3 | NCT03813394 |
| CapecitabineXeloda, Capectitabine Tablets | II | 3 | NCT07524413 |
| PembrolizumabKEYTRUDA, MK-3475 | I–II | 3 | NCT03813394 |
| NivolumabOpdivo, ONO-4538 | II | 2 | NCT04875611 |
| ToripalimabJS001, Teripalimab | II | 2 | NCT05628922 |
| AtezolizumabTecentriq, MPDL3280A | II | 1 | NCT03074513 |
| DocetaxelTaxotere, Beizray® | II | 1 | NCT06892431 |
| Interferon beta-1aRebif®, Avonex® | II | 1 | NCT06019130 |
| PenpulimabAK105, Penplimab Injection | II | 1 | NCT05807880 |
| CemiplimabREGN2810, Libtayo® | I | 1 | NCT07650266 |
Sorted by most advanced phase and number of active trials.
All 32 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Nasopharyngeal Carcinoma 71 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Metastasis 493 drugs
- Laryngeal neoplasm 35 drugs
- Mouth Neoplasms 49 drugs
- Carcinoma 137 drugs
- Hypopharyngeal Neoplasms 33 drugs
- Oropharyngeal Neoplasms 46 drugs
- Non-small-cell lung carcinoma 726 drugs
- Renal cell carcinoma 228 drugs
- Melanoma 352 drugs
- Transitional cell carcinoma 146 drugs
Broader categories
- Otorhinolaryngologic disease 4 drugs
- Pharyngeal Neoplasms 5 drugs
- Stomatognathic disease 4 drugs
- Nasopharyngeal disease 3 drugs
- Neoplasm 671 drugs
- Head and neck neoplasms 184 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009303 “Nasopharyngeal Neoplasms”.